Bayer Initiates Legal Action Against COVID-19 Vaccine Manufacturers Over mRNA Technology

Bayer, through its subsidiary Monsanto, has filed lawsuits against Pfizer, BioNTech, and Moderna, alleging that these companies misappropriated its messenger RNA (mRNA) technology in the development of their COVID-19 vaccines. The lawsuits were filed in federal courts in Delaware and New Jersey, with Bayer claiming that the defendants utilized patented technology originally developed by Monsanto in the 1980s to enhance mRNA stability in crops. This technology, which was designed to improve agricultural output, is now at the center of Bayer's claims regarding its application in vaccine production.

FiercePharmaBayer sues C-19 vaccine makers over misuse of mRNA technologyBayer sues Covid-jab makers, alleging patent violationThe IndependentPharmaphorumABC News Australia

Bayer's lawsuits assert that Pfizer and BioNTech's Comirnaty and Moderna's Spikevax vaccines incorporated methods to eliminate problematic coding sequences in mRNA, thereby improving the stability and efficacy of the vaccines. The patents in question, awarded to Monsanto in 2010, are set to remain valid until June 2027. Bayer is seeking unspecified monetary damages and royalties from the sales of these vaccines, although it has clarified that it does not intend to halt their production.

PharmaphorumBayer sues C-19 vaccine makers over misuse of mRNA technologyFiercePharmaThe IndependentBayer sues Covid-jab makers, alleging patent violationABC News Australia

The financial stakes are significant, with Pfizer and BioNTech reporting over $3.3 billion in revenue from Comirnaty in 2024, while Moderna earned approximately $3.2 billion from Spikevax. Bayer's legal actions come amidst a broader landscape of patent disputes involving multiple companies in the mRNA vaccine sector, including ongoing litigation between Moderna and Pfizer.

Pharmaphorum

While Bayer has positioned itself as a protector of its intellectual property, the defendants have expressed confidence in their own patent rights. Pfizer, BioNTech, and Moderna have indicated their intention to defend against these claims vigorously. Critics of Bayer's lawsuits may argue that the company, which did not participate in the development of COVID-19 vaccines, is leveraging its patents to capitalize on the success of these vaccines without having contributed to their creation.

FiercePharmaBayer sues C-19 vaccine makers over misuse of mRNA technologyABC News AustraliaPharmaphorumBayer sues Covid-jab makers, alleging patent violationThe Independent

There is a notable absence of comments from Pfizer, BioNTech, and Johnson & Johnson regarding the lawsuits, which raises questions about their legal strategies and potential defenses. Additionally, while Bayer seeks damages, the specific amount and the basis for its claims remain unspecified, leaving some ambiguity in the legal proceedings.

FiercePharma

• “This lawsuit alleges the defendants infringed on patented innovations owned by Bayer which increase mRNA stability and which Bayer initially used for agricultural purposes,” — Bayer Spokesperson

Bayer sues Covid-jab makers, alleging patent violation

• “To develop effective mRNA medicines, defendants needed to stabilise the mRNA molecule and optimise its protein expression,” — Bayer's Complaint

Pharmaphorum

Bayer's lawsuits against Pfizer, BioNTech, Moderna, and Johnson & Johnson highlight the complexities of intellectual property rights in the rapidly evolving field of mRNA technology. As the legal proceedings unfold, they will likely have implications not only for the companies involved but also for the broader landscape of vaccine development and patent law.

Bayer sues Covid-jab makers, alleging patent violation